![Mark Lappe](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark Lappe
Nessuna posizione attualmente
Patrimonio netto: 12 M $ in data 31/05/2024
Profilo
Mr. Mark P.
Lappe is a Managing Partner at Efficacy Capital Ltd.
and a Chairman, President & Chief Executive Officer at Inhibrx Biosciences, Inc. Mr. Lappe was previously employed as a Chairman, President & Chief Executive Officer by Inhibrx, Inc., a Chief Executive Officer by Inhibrx LP, a Non-Executive Director by Osmetech Plc, a Chairman by Repros Therapeutics, Inc., a Founder by Efficacy Capital LLC, a Founder by Lappe & Associates, Inc., and a Managing Partner by Efficacy Biotech Fund LP.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
5.26% | 30/05/2024 | 761 413 ( 5.26% ) | 12 M $ | 31/05/2024 |
Posizioni attive di Mark Lappe
Società | Posizione | Inizio |
---|---|---|
Efficacy Capital Ltd. | Corporate Officer/Principal | 10/06/2009 |
Precedenti posizioni note di Mark Lappe
Società | Posizione | Fine |
---|---|---|
INHIBRX, INC. | Amministratore Delegato | 30/05/2024 |
REPROS THERAPEUTICS INC | Presidente | 12/11/2009 |
Osmetech Ltd.
![]() Osmetech Ltd. Medical/Nursing ServicesHealth Services Osmetech Ltd. designs, develops, manufactures and sells molecular diagnostics instruments and consumables enabling deoxyribonucleic acid, ribonucleic acid and protein testing. Its operates in Atlanta, Boston and Pasadena in the US, serving the growth, near patient testing market targeting small to medium sized hospitals. Osmetech was founded in 1993 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | 28/08/2009 |
Efficacy Biotech Fund LP | Fondatore | - |
Inhibrx LP
![]() Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Amministratore Delegato | - |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 8 |
---|---|
Repros Therapeutics, Inc.
![]() Repros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Repros Therapeutics, Inc. is a development stage biopharmaceutical company, which focuses on the development of drugs to treat hormonal and reproductive systems disorders. Its products include Enclomiphene and Proellex. The company was founded on August 20, 1987 and is headquartered in The Woodlands, TX. | Health Technology |
Osmetech Ltd.
![]() Osmetech Ltd. Medical/Nursing ServicesHealth Services Osmetech Ltd. designs, develops, manufactures and sells molecular diagnostics instruments and consumables enabling deoxyribonucleic acid, ribonucleic acid and protein testing. Its operates in Atlanta, Boston and Pasadena in the US, serving the growth, near patient testing market targeting small to medium sized hospitals. Osmetech was founded in 1993 and is headquartered in London, the United Kingdom. | Health Services |
Efficacy Capital Ltd. | |
Lappe & Associates, Inc. | |
Efficacy Capital LLC
![]() Efficacy Capital LLC Investment ManagersFinance Founded in 2004 by Mark Paul Lappe and Jon Faiz Kayyem, Efficacy Capital LLC is a hedge fund manager located in La Jolla, California. The firm provides investment management services primarily to high net-worth individuals. They also manage pooled investment vehicles, including hedge funds and mutual funds | Finance |
Inhibrx LP
![]() Inhibrx LP BiotechnologyHealth Technology Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA. | Health Technology |
Efficacy Biotech Fund LP | |
Inhibrx, Inc.
![]() Inhibrx, Inc. BiotechnologyHealth Technology Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA. | Health Technology |
- Borsa valori
- Insiders
- Mark Lappe